Tarsus Pharmaceuticals, Inc. (TARS) vs Viking Therapeutics, Inc. (VKTX)
A side-by-side comparison of Tarsus Pharmaceuticals, Inc. and Viking Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
TARS
Tarsus Pharmaceuticals, Inc.
$74.11HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
VKTX
Viking Therapeutics, Inc.
$28.38HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — TARS vs VKTX
growth of $100 · dividends reinvested · last 6yTARS +261.8% (+23.9%/yr)VKTX +399.7% (+30.8%/yr)VKTX compounded faster over this window
TARS VKTX
TARS vs VKTX: by the numbers
- •VKTX is the larger company ($3.31B vs $3.19B market cap).
- •Both run net losses; VKTX's is the smaller (0.00% vs -7.67% net margin).
Metrics side by side
Valuation
| Metric | TARS | VKTX |
|---|---|---|
| P/S ratio | 5.26 | N/A |
| P/B ratio | 9.20 | 8.11 |
| FCF yield | 1.93% | N/A |
Profitability
| Metric | TARS | VKTX |
|---|---|---|
| Gross margin | 90.59% | 0.00% |
| Operating margin | -8.00% | 0.00% |
| Net margin | -7.67% | 0.00% |
| ROE | -13.40% | -130.98% |
| ROIC | -11.15% | -135.85% |
Growth (annualized)
| Metric | TARS | VKTX |
|---|---|---|
| Revenue CAGR (5Y) | 61.36% | N/A |
| Total return CAGR (5Y) | 28.33% | 37.36% |
Frequently asked
- How have TARS and VKTX total returns compared?
- Over the past 5 years, TARS delivered 28.33% and VKTX delivered 37.36% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Tarsus Pharmaceuticals ROEViking Therapeutics ROETarsus Pharmaceuticals operating marginViking Therapeutics operating marginTarsus Pharmaceuticals revenue growthViking Therapeutics revenue growthTarsus Pharmaceuticals free cash flowViking Therapeutics free cash flow
Tarsus Pharmaceuticals & Viking Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.